In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...
Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not ...
Patients in cohort 9 received enfortumab vedotin at 1.25 mg/kg intravenously on days 1 and 8 plus pembrolizumab at 200 mg intravenously on day 1 of each 21-day cycle. Treatment was administered until ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback